NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10,575 mln
Float123 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
1.16
Highly suspicious
1-Year Forecast
88.17
Attractive
Relative Strength
82
/ 100
Strongly outperforming
Debt / Equity
1.61
High leverage
ROE
-52.72
Deeply negative
Business Description
Arrowhead Pharmaceuticals is a US-based drug development company focused on creating treatments for serious and hard-to-treat diseases. The company uses RNA interference technology to develop a broad range of experimental therapies targeting conditions related to the liver, heart, kidneys, and other areas, with several candidates already in advanced clinical trials. Arrowhead works alongside major pharmaceutical partners including GSK, Takeda, Amgen, and Sarepta Therapeutics. Founded in 2003 and based in Pasadena, California, the company continues to grow its pipeline of next-generation medicines.
